Cumulus Neuroscience

22/12/2022

At Cumulus Neuroscience, our User Advisory Panel is made up of people living with dementia and patient advocates (e.g., family members, carers, or those who work with people with dementia). Panel members occasionally test our products and provide us with feedback to ensure we’re developing our platform with patient needs in mind.

We’re currently looking for new panel members to offer some fresh perspectives on our headset and app. We are especially keen to invite people who are living with early stage dementia, and welcome their carers to take part alongside them (both receiving compensation for their time).

For more information about the Cumulus User Advisory Panel, visit https://bit.ly/3BTNn2r

10/10/2022

Happy . The theme of 2022's World Mental Health Day, set by the World Federation for Mental Health, is 'Make mental health and wellbeing for all a global priority'. 💚🌎

26/08/2022

Bioworld write about the success of our validation study and how Cumulus' at-home EEG demonstrated superiority to lab-based measurement. CSO Brian Murphy discusses the exciting results with Nuala Moran and what this could mean for the future of and . Paywall link:

Cumulus Neuroscience Ltd. published a study demonstrating its home use electroencephalogram (EEG) can turn in more precise results than supervised laboratory-based assessments.

22/07/2022

Today is . There are many remaining unmet needs in the treatment of and diseases, but by working to improve the robustness of clinical trials we can accelerate the development of impactful new pharmaceuticals.

At Cumulus, using cutting edge -based data analysis we are developing a next generation integrated digital and physiological biomarker platform, designed to greatly improve the measurement of disease progression in brain disorders and provide insights needed to enhance the development of therapies for patients.

13/07/2022

This week our CSO Brian Murphy is taking part in a BrainMind/OECD Neuroethics Global Advisory Meeting. Cumulus Neuroscience is proud to play its part in setting international guidelines for ethical treatment of data in

On July 11-12, 2022, BrainMind and the OECD Working Party on Bio-, Nano-, and Converging Technologies (BNCT) will convene a group of interdisciplinary leaders to advise on how to secure the role of neuroethics in the future of neuroscience research and in its applications to human brain health and f...

08/11/2021

If you're attending be sure to catch our CSO Brian Murphy and other & experts discussing 'Pioneering disease-modifying treatments and digital solutions for dementia' on Weds 10am GMT. Register here: https://pharma.live.ft.com/home

01/10/2021

2 days to go until the Belfast City Marathon!
Please support our fundraising effort for Alzheimer’s Society!
https://tinyurl.com/3feej25b

Cumulus Neuroscience have entered 2 teams into the 2021 Belfast City Marathon Relay.

Alzheimer’s Society is transforming the landscape of dementia forever. Until the day we find a cure, we will create a society where those affected by dementia are supported and accepted, able to live in their community without fear or prejudice.

Deep RiverRock Belfast City Marathon

Help Cumulus Neuroscience Ltd raise money to support Alzheimer's Society

24/09/2021

https://www.irishtimes.com/business/technology/tech-sector-accounts-for-more-than-one-in-seven-northern-irish-jobs-1.4681814

Belfast named as a tech hub to watch due to number of start-ups in the city

14/09/2021

Cumulus Neuroscience Appoints Dr Ruth McKernan CBE as Chair
https://tinyurl.com/6b3tb4t7

19/08/2021

Great change starts with good charity

Today 50 million people suffer from dementia across the world, and that number is expected to grow. About two thirds of those cases are caused by Alzheimer’s Disease. The world urgently needs new therapies and technologies, both for prevention and cure.

The Alzheimer’s Society is the UK’s leading dementia charity. They are investing more money than ever in dementia research and attracting more talent to the effort. But like many charities their fund-raising has fallen during the COVID-19 pandemic, and they need your help!

At Cumulus, our mission is to help transform treatment in brain health – and that means working directly with patients, and the wider dementia community. To support Alzheimer’s Society in their fundraising, we have entered two teams into the 2021 Belfast City Marathon.
We have dusted off our trainers and are ready to run to help make a difference! If you would like to support us, please click on the link below to make a donation. All donations will go to Alzheimer's Society.

https://www.justgiving.com/fundraising/cumulus-neuroscience-ltd

13/05/2021

It's mental health awareness week. At Cumulus Neuroscience we are proud to support research studies and clinical trials investigating new therapies for neuropsychiatric disorders.

12/05/2021

Cumulus Neuroscience announces £6 million funding round led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund.

Cumulus Neuroscience’s CSO Brian Murphy commented: “Clinical scientists today lack practical and effective tools to objectively track symptoms and progression of neurological conditions. Drug development professionals suffer from this problem when they aim to prove out new ground-breaking therapies for these diseases. We are working with a group of the top pharmaceutical companies, and have co-designed a single technology solution that addresses this — making it possible for the first time to measure the full spectrum of effects from drug mechanisms and neurobiology, to symptoms and real-life function, frequently and conveniently in the home.”


Read the press release here:
https://tinyurl.com/3m4ndz7r

07/05/2021

Cumulus Neuroscience announces £6 million funding round led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund.

Ruth McKernan DDF venture partner and co-founder said: “Clinical trials in dementia are difficult and the results have been largely disappointing, partly due to the limitations of clinical trial methodology. My colleagues in the DDF and a group of Pharma companies and I have spent over a year working together on how to measure disease progression and the effects of drugs better. The result is Cumulus Neuroscience and we look forward to seeing the platform used in dementia clinical studies in the coming years. If the platform is successful, then patients will benefit from better drugs sooner."


Read the press release here:
https://tinyurl.com/3m4ndz7r

06/05/2021

Cumulus Neuroscience announces £6 million funding round led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund.

Cumulus Neuroscience’s CEO Ronan Cunningham commented: “We are delighted that DDF and LifeArc share our mission, addressing the clear need for more effective tools to provide the critical clinical trial data and analysis needed to improve the successful delivery of new therapies to patients. This funding will allow us to build on the ground-breaking advances we have made in remote, frequent monitoring of brain activity and cognitive function in the home, in partnership with leading developers of digital biomarkers. We believe our integrated next generation platform can improve the ex*****on of clinical trials by yielding significant time and cost savings, adding significant value to the next generation of CNS therapies.”


Read the press release here:
https://tinyurl.com/3m4ndz7r